[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-337253-105":59,"doc-detail-337253-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","neutralizing-gdf-15-can-overcome-anti-pd-1-and-anti-pd-l1-resistance-in-solid-tumours","Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours","","Cancer immunotherapies using antibodies that block immune checkpoint molecules are active across many cancer types, yet response rates remain limited and tumour progression is common. Factors within the tumour microenvironment suppress anti-tumour immunity. Growth differentiation factor 15 (GDF-15), a cytokine produced by many cancers, interferes with immune responses; preclinical studies show that GDF-15 blockade can synergize with anti-PD-1 inhibition.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/neutralizing-gdf-15-can-overcome-anti-pd-1-and-anti-pd-l1-resistance-in-solid-tumours/337253/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/neutralizing-gdf-15-can-overcome-anti-pd-1-and-anti-pd-l1-resistance-in-solid-tumours/337253.png","ImageObject",300,407,{"name":92,"@type":93},"Aurelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why target GDF-15 in cancer immunotherapy?","Question",{"text":112,"@type":113},"GDF-15 is produced abundantly by many cancer types and can interfere with antitumour immune responses, contributing to immune suppression in the tumour microenvironment.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was visugromab (CTL-002) tested in the GDFATHER-1/2a trial?",{"text":117,"@type":113},"In a first-in-human phase 1–2a study, patients with advanced cancers refractory to anti-PD-1 or anti-PD-L1 received neutralizing anti-GDF-15 antibody visugromab in combination with nivolumab.",{"name":119,"@type":110,"acceptedAnswer":120},"What response effects were reported in patients treated with visugromab plus nivolumab?",{"text":121,"@type":113},"Durable and deep responses were observed in some patients with non-squamous non-small cell lung cancer and urothelial cancer, accompanied by increased cytotoxic T cell infiltration and granzyme B expression.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},337253,1790168444,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":41,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1794309523707217728","Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours  \n\n| [https://doi.org/10.1038/s41586-024-08305-z](https://doi.org/10.1038/s41586-024-08305-z)\u003Cbr>Received: 1 March 2024 Accepted: 29 October 2024 Published online: 11 December 2024 Open access\u003Cbr> Check for updates | Ignacio Melero1,2 ✉, Maria de Miguel Luken3, Guillermo de Velasco4, Elena Garralda5,\u003Cbr>Juan Martín-Liberal6, Markus Joerger7, Guzman Alonso8, Maria-Elisabeth Goebeler9,\u003Cbr>Martin Schuler10,11, David König12, Reinhard Dummer13, Maria Reig14,15,\u003Cbr>Maria-Esperanza Rodriguez Ruiz16, Emiliano Calvo3, Jorge Esteban-Villarrubia4, Arjun Oberoi5, Paula Sabat6, Juan José Soto-Castillo6, Kira-Lee Koster7, Omar Saavedra8, Cyrus Sayehli9, Tanja Gromke10,11, Heinz Läubli12, Egle Ramelyte13, Marta Fortuny14,15, Ana Landa-Magdalena16, Irene Moreno3, Javier Torres-Jiménez4, Alberto Hernando-Calvo5, Dagmar Hess7,\u003Cbr>Fabricio Racca8, Heike Richly10,11, Andreas M. Schmitt12, Corinne Eggenschwiler13,\u003Cbr>Marco Sanduzzi-Zamparelli14,15, Anna Vilalta-Lacarra16, Jörg Trojan17, Christine Koch17,\u003Cbr>Peter R. Galle18, Friedrich Foerster18, Zlatko Trajanoski19, Hubert Hackl19, Falk Gogolla19, Florestan J. Koll20, Peter Wild21, Felix Kyoung Hwan Chun20, Henning Reis21, Peter Lloyd22, Matthias Machacek23, Thomas F. Gajewski24, Wolf H. Fridman25, Alexander M. M. Eggermont26,27, Ralf Bargou28, Sandra Schöniger29, Josef Rüschoff29, Anastasiia Tereshchenko29,\u003Cbr>Carina Zink30, Antonio da Silva31, Felix S. Lichtenegger32, Julia Akdemir32, Manfred Rüdiger32, Phil L’Huillier32, Aradhana Dutta32, Markus Haake32, Alexandra Auckenthaler32, Ana Gjorgjioska32, Bernhard Rössler32, Frank Hermann32, Mara Liebig32, Daniela Reichhardt32, Christine Schuberth-Wagner32, Jörg Wischhusen33, Petra Fettes32, Marlene Auer32,\u003Cbr>Kathrin Klar32,34 & Eugen Leo32,34✉\u003Cbr>Cancer immunotherapies with antibodies blocking immune checkpoint molecules are clinically active across multiple cancer entities and have markedly improved cancer treatment1. Yet, response rates are still limited, and tumour progression commonly occurs2. Soluble and cell-bound factors in the tumour microenvironment negatively affect cancer immunity. Recently, growth differentiation factor 15 (GDF-15), a cytokine that is abundantly produced by many cancer types, was shown to interfere with antitumour immune response. In preclinical cancer models, GDF-15 blockade synergistically enhanced the efficacy of anti-PD-1-mediated checkpoint inhibition3. Ina first-in-human phase 1–2a study (GDFATHER-1/2atrial, NCT04725474), patients with advanced cancers refractory to anti-PD-1 or anti-PD-L1 therapy (termed generally as anti-PD-1/PD-L1 refractoriness) were treated with the neutralizing anti-GDF-15 antibody visugromab (CTL-002) in combination with the anti-PD-1 antibody nivolumab. Here we show that durable and deep responses were achieved in some patients with non-squamous non-small cell lung cancer and urothelial cancer, two cancer entities identified as frequently immunosuppressed by GDF-15 inan insilico screening of approximately 10,000 tumour samples in The Cancer Genome Atlas database. Increased levels of tumour infiltration, proliferation, interferon-γ-related signalling and granzyme Bexpression by cytotoxic T cells were observed in response to treatment. Neutralizing GDF-15 holds promise in overcoming resistance to immune checkpoint inhibition in cancer. |  |\n| --- | --- | --- |\n| Empowering the immune system to fight cancer has revolutionized |  | divergent TGFβ superfamily member GDF-15 (ref. 6), which is expressed |\n| tumour treatment in the past two decades1. Anti-PD-1 and anti-PD-L1 |  | at high levels in placenta and solid tumours, stands out asa prominent |\n| antibodies are now established asa standard of care for first-line treat- |  | molecule used by tumours to keep the immune system at bay3. This mir- |\n| ment of cancer. However, response rates of just 15–50% in many solid |  | rors the physiological role of GDF-1","cbCaig5BvoJjg4xz","https://ap.wps.com/l/cbCaig5BvoJjg4xz","pdf",14705279,"English","# Background\n# Rationale for targeting GDF-15\n# GDFATHER-1/2a clinical trial overview\n# Key observations and translational findings\n# Implications for overcoming resistance","[{\"question\":\"Why target GDF-15 in cancer immunotherapy?\",\"answer\":\"GDF-15 is produced abundantly by many cancer types and can interfere with antitumour immune responses, contributing to immune suppression in the tumour microenvironment.\"},{\"question\":\"How was visugromab (CTL-002) tested in the GDFATHER-1/2a trial?\",\"answer\":\"In a first-in-human phase 1–2a study, patients with advanced cancers refractory to anti-PD-1 or anti-PD-L1 received neutralizing anti-GDF-15 antibody visugromab in combination with nivolumab.\"},{\"question\":\"What response effects were reported in patients treated with visugromab plus nivolumab?\",\"answer\":\"Durable and deep responses were observed in some patients with non-squamous non-small cell lung cancer and urothelial cancer, accompanied by increased cytotoxic T cell infiltration and granzyme B expression.\"}]","Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours | PDF",1790018354,76,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d7d2efbaf0ad62b541a40c81413bf91c.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/42d297c36c024f50048cc8954e4161a7.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7f9c2a04e9bf47470c27b7d93fb4b221.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c2e5fe0a54db322b2ba697f7c874f4a1.webp",980,1301]